You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Medtronic
Harvard Business School
Colorcon
McKinsey

Last Updated: December 4, 2023

VYVANSE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Vyvanse, and when can generic versions of Vyvanse launch?

Vyvanse is a drug marketed by Takeda Pharms Usa and is included in two NDAs. There are eighteen patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and forty-eight patent family members in twenty-seven countries.

The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. Twelve suppliers are listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.

Paragraph IV (Patent) Challenges for VYVANSE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VYVANSE Capsules lisdexamfetamine dimesylate 10 mg 021977 1 2020-04-09
VYVANSE Capsules lisdexamfetamine dimesylate 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg 021977 6 2011-02-23

US Patents and Regulatory Information for VYVANSE

VYVANSE is protected by eighteen US patents.

Patents protecting VYVANSE

Abuse-resistant amphetamine compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse resistant lysine amphetamine compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse-resistant amphetamine prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse-resistant amphetamine prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse-resistant amphetamine prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse resistant lysine amphetamine compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse-resistant amphetamine prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse-resistant amphetamine prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse-resistant amphetamine prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse-resistant amphetamine prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse-resistant amphetamine prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse-resistant amphetamine prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse-resistant amphetamine prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse-resistant amphetamine prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse-resistant amphetamine prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse-resistant amphetamine prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse-resistant amphetamine prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Abuse-resistant amphetamine prodrugs
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa VYVANSE lisdexamfetamine dimesylate CAPSULE;ORAL 021977-002 Feb 23, 2007 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Takeda Pharms Usa VYVANSE lisdexamfetamine dimesylate CAPSULE;ORAL 021977-006 Dec 10, 2007 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Takeda Pharms Usa VYVANSE lisdexamfetamine dimesylate CAPSULE;ORAL 021977-001 Feb 23, 2007 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Takeda Pharms Usa VYVANSE lisdexamfetamine dimesylate CAPSULE;ORAL 021977-004 Dec 10, 2007 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Takeda Pharms Usa VYVANSE lisdexamfetamine dimesylate TABLET, CHEWABLE;ORAL 208510-003 Jan 28, 2017 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Takeda Pharms Usa VYVANSE lisdexamfetamine dimesylate TABLET, CHEWABLE;ORAL 208510-002 Jan 28, 2017 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VYVANSE

See the table below for patents covering VYVANSE around the world.

Country Patent Number Title Estimated Expiration
Australia 2004251647 Abuse resistant amphetamine compounds ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 0234237 ⤷  Try a Trial
Egypt 26032 مركبات امفيتامينية مقاومة اساءه الاستخدام (Abuse resistant amphetamine compounds) ⤷  Try a Trial
European Patent Office 1531844 NOUVEAUX COMPOSÉS PHARMACEUTIQUES A LIBÉRATION PROLONGÉE DESTINÉS A EMPÊCHER LA CONSOMMATION ABUSIVE DE SUBSTANCES CONTROLÉES (NOVEL SUSTAINED RELEASE PHARMACEUTICAL COMPOUNDS TO PREVENT ABUSE OF CONTROLLED SUBSTANCES) ⤷  Try a Trial
Brazil PI0410792 compostos de anfetamina resistentes a abuso ⤷  Try a Trial
Slovenia 1644019 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VYVANSE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1644019 LUC00189 Luxembourg ⤷  Try a Trial PRODUCT NAME: LISDEXAMFETAMINE, OPTIONALLY IN THE FORM OF A MESYLATE OR HYDROCHLORIDE SALT THEREOF; AUTHORISATION NUMBER AND DATE: PL08081/0050-52 20200901
1644019 549 Finland ⤷  Try a Trial
1644019 C01644019/01 Switzerland ⤷  Try a Trial VERTRETERLOESCHUNG
1644019 1390058-4 Sweden ⤷  Try a Trial PRODUCT NAME: LISDEXAMFETAMIN VALFRITT I FORMEN AV ETT FARMACEUTISKT GODTAGBART SALT, SAERSKILT ETT MESYLATSALT; NAT. REG. NO/DATE: 47382 20130722; FIRST REG.: GB PL 08081/0050-52 20130201
1644019 122013000079 Germany ⤷  Try a Trial PRODUCT NAME: LISDEXAMFETAMINE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DESSEN, WIE L-LYSIN-D-AMPHETAMIN-MESYLAT; REGISTRATION NO/DATE: 86155.00.00 86156.00.00 86157.00.00 20130318; FIRST REGISTRATION: UK PL 08081/0050-2 20130201
1644019 CR 2013 00043 Denmark ⤷  Try a Trial PRODUCT NAME: LISDEXAMFETAMIN, EVENTUELT I FORM AF ET MESYLAT ELLER HYDROCHLORID SALT DERAF; NAT. REG. NO/DATE: MT499080, MT499081, MT499082 20130214; FIRST REG. NO/DATE: PL PL 08081/0050-0052 20130201
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
AstraZeneca
Colorcon
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.